Daniel Naberhaus, MD
Family Medicine · Arlington, TXNPI 1891728572
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 436 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$724
- AstraZeneca$683
- AbbVie$665
- Boehringer Ingelheim$550
- Pfizer$425
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,138 |
| Lilly USA, LLC | 51 | $724 |
| AstraZeneca | 40 | $683 |
| AbbVie(2 entities) | 40 | $665 |
| Boehringer Ingelheim | 34 | $550 |
| Pfizer | 29 | $425 |
| GSK | 16 | $298 |
| Merck | 19 | $268 |
| Bayer | 14 | $245 |
| Amgen | 14 | $236 |
| Eisai Inc. | 13 | $216 |
| Astellas Pharma US Inc | 10 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Sanofi-aventis U.S. LLC | 6 | $129 |
| Kowa Pharmaceuticals America, Inc. | 9 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Amarin Pharma, Inc. | 7 | $95 |
| Johnson & Johnson | 6 | $86 |
| Exact Sciences | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Novartis | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 3 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $23 |
| Genentech USA, Inc. | 2 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Abbott | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$6,854 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $115,138 |
| EliquisApixaban | 90 | $103,475 |
| JardianceEmpagliflozin | 36 | $47,467 |
| RybelsusSemaglutide | 25 | $45,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $45,451 |
| LinzessLinaclotide | 36 | $29,017 |
| XareltoRivaroxaban | 29 | $25,606 |
| FarxigaDapagliflozin Propanediol | 31 | $25,375 |
| MyrbetriqMirabegron | 36 | $23,938 |
| JanuviaSitagliptin Phosphate | 19 | $18,469 |
| MounjaroTirzepatide | 14 | $18,381 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $16,549 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,242 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,795 |
| Colchicine | 20 | $5,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,138 | $160,981127 claims |
| PfizerEliquis | $425 | $103,47590 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $298 | $52,24672 claims |
| Boehringer IngelheimJardiance | $550 | $47,46736 claims |
| AbbVieLinzess | $665 | $29,01736 claims |
| AstraZenecaFarxiga, Symbicort | $683 | $28,02442 claims |
| Johnson & JohnsonXarelto | $86 | $25,60629 claims |
| Astellas Pharma US IncMyrbetriq | $187 | $23,93836 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $724 | $20,51727 claims |
| MerckJanuvia | $268 | $18,46919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Bradley WassonArlington$734K
- Gilbert LedesmaArlington$34K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.